Related Experiment Videos
Evidence that protein kinase C regulates allosensitized T lymphocyte function
1Department of Surgery, University of Pittsburgh, School of Medicine, Pennsylvania 15213.
The Journal of Surgical Research
|June 1, 1991
Summary
Protein kinase C (PKC) activation significantly enhances allosensitized T cell proliferation and migration. Inhibiting PKC reduced these functions, suggesting PKC is crucial for T cell responses in allograft rejection.
Area of Science:
- Immunology
- Cellular Biology
- Molecular Signaling
Background:
- The role of second messengers in T cell alloactivation remains unclear.
- Intracellular calcium has been identified as a potential T-cell alloactivation marker.
- The involvement of protein kinase C (PKC) in allosensitized T cell function requires investigation.
Purpose of the Study:
- To investigate the role of protein kinase C (PKC) in the proliferation and migration of allosensitized T cells.
- To determine the effects of PKC agonists and antagonists on T cell function in vitro.
- To explore potential therapeutic pathways for modifying T cell function in allograft responses.
Main Methods:
- Utilized a mixed leukocyte culture (MLC) model using C57BL/6 anti-DBA/2J cells.
- Administered PKC agonists (phorbol 12-myristate 13-acetate, mezerein, OAG) and antagonists (phloretin, D-sphingosine).
- Assessed T cell proliferation and in vitro locomotion using a Boyden chamber assay.
Main Results:
- PKC agonists, particularly PMA, significantly stimulated secondary MLC supernatant-induced T cell proliferation (132-200% increase).
- MEZ and OAG also demonstrated stimulatory effects on T cell proliferation (132-152% of control).
- PKC antagonists phloretin and D-sphingosine inhibited proliferation by over 50% and affected T cell locomotion.
Conclusions:
- PKC activation plays a significant role in promoting allosensitized T cell proliferation and locomotion.
- PKC represents a potential molecular pathway for modulating T cell function in the context of allograft responses.
- Targeting PKC could offer novel strategies for managing allograft rejection.